Atea Pharmaceuticals (AVIR) Retained Earnings (2020 - 2022)
Atea Pharmaceuticals (AVIR) has 3 years of Retained Earnings data on record, last reported at -$25.4 million in Q3 2022.
- For Q3 2022, Retained Earnings rose 58.35% year-over-year to -$25.4 million; the TTM value through Sep 2022 reached -$25.4 million, up 58.35%, while the annual FY2021 figure was $56.0 million, 185.99% up from the prior year.
- Retained Earnings reached -$25.4 million in Q3 2022 per AVIR's latest filing, down from -$17.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $56.0 million in Q4 2021 and bottomed at -$85.8 million in Q3 2020.
- Average Retained Earnings over 3 years is -$28.0 million, with a median of -$32.9 million recorded in 2021.
- The widest YoY moves for Retained Earnings: up 185.99% in 2021, down 28.8% in 2021.
- A 3-year view of Retained Earnings shows it stood at -$65.2 million in 2020, then skyrocketed by 185.99% to $56.0 million in 2021, then tumbled by 145.42% to -$25.4 million in 2022.
- Per Business Quant database, its latest 3 readings for Retained Earnings were -$25.4 million in Q3 2022, -$17.4 million in Q2 2022, and $14.0 million in Q1 2022.